US FDA Throws Acadia A Curveball On Nuplazid For Dementia Psychosis
Complete Response Letter Requires More Data
Acadia strikes out on potential near-term sNDA approval in a broad dementia-related psychosis indication. The firm said the agency’s view has shifted from what was previously agreed upon.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
An analyst had suggested that in the event of a thumbs-down from the FDA, the company could end up focusing on other catalysts instead.
Regeneron's COVID-19 antibody cocktail helped drive 38% growth for the company, while Global Blood Therapeutics' Oxbryta continues to face headwinds and Horizon focuses on relaunches.